RxDoctor Payments Data

Felicia Dejesus, MD

Psychiatry · Lancaster, PANPI 1104138676

Payments from drug & device makers

$9,006in general payments, 2019–2025

Across 542 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$1K
  • Lundbeck LLC$963
  • AbbVie$939
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$928
  • Otsuka America Pharmaceutical, Inc.$742
  • Sunovion Pharmaceuticals Inc.$680
  • plus $3K from 14 others

What the payments were for

  • Food & beverage$8,95199%
  • Education$561%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,006 in reported general payments places this provider in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$48,353
Medicare patients
58
Services billed
549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate14$112,187
RexultiBrexpiprazole41$57,032
VraylarCariprazine Hcl33$50,393
Abilify MaintenaAripiprazole15$42,035
LybalviOlanzapine/Samidorphan Malate15$21,553
Aripiprazole63$9,819
LunestaEszopiclone11$9,172
Clozapine85$8,420
Adderall XrDextroamphetamine/Amphetamine11$4,858
Fluoxetine Hcl130$2,657
Lurasidone Hcl18$2,370
Venlafaxine Hcl ErVenlafaxine Hcl102$2,235
Hydroxyzine Hcl138$2,111
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine15$2,070
Quetiapine Fumarate129$1,935

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$626$112,18714 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$742$99,06756 claims
AbbVieVraylar$939$50,39333 claims
Alkermes, Inc.Lybalvi$1,390$21,55315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.

Other psychiatry in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →